Skip to main content

Table 4 Multivariate analysis of prognostic factors for LRFS, LNMFS, DMFS, RFS, and OS

From: Impact of preoperative anemia on relapse and survival in breast cancer patients

  LRFS LNMFS DMFS RFS OS      
  HR (95% CI) P HR (95% CI) P 95% CI P 95% CI P 95% CI P
T stage           
    T1 Ref   NS NS Ref   Ref   Ref  
    T2 1.045 (0.532–2.050) 0.899 NS NS 1.333 (0.962–1.847) 0.084 1.287 (0.976–1.697) 0.074 1.291 (0.925–1.803) 0.134
    ≥T3 2.676 (1.267–5.653) 0.010 NS NS 1.983 (1.347–2.920) 0.001 2.021 (1.455–2.807) <0.001 2.020 (1.371–2.975) <0.001
N stage           
    N0 Ref   Ref   Ref   Ref   Ref  
    N1 2.601 (1.366–4.963) 0.004 2.235 (1.366–3.657) 0.001 2.040 (1.493–2.788) <0.001 2.009 (1.544–2.615) <0.001 1.942 (1.404–2.687) <0.001
    N2 2.708 (1.122–6.534) 0.027 3.742 (2.058–6.805) <0.001 3.484 (2.358–5.147) <0.001 3.016 (2.152–4.225) <0.001 4.200 (2.854–6.181) <0.001
    N3 2.450 (0.859–6.989) 0.094 2.045 (0.912–4.487) 0.083 4.822 (3.175–7.323) <0.001 3.856 (2.672–5.565) <0.001 5.083 (3.307–7.812) <0.001
    ER           
    Negative Ref   NS NS Ref   Ref   Ref  
    Positive 0.525 (0.261–1.057) 0.071 NS NS 0.670 (0.479–0.937) 0.019 0.726 (0.547–0.965) 0.027 0.845 (0.598–1.194) 0.340
    Strongly positive 0.340 (0.144–0.803) 0.014 NS NS 0.804 (0.537–1.206) 0.292 0.757 (0.534–1.074) 0.119 0.566 (0.360–0.890) 0.014
PR           
    Negative Ref   NS NS NS NS Ref NS NS NS
    Positive 1.709 (0.826–3.535) 0.149 NS NS NS NS 1.409 (1.066–1.861) 0.016 NS NS
    Strongly positive 2.989 (1.236–7.228) 0.015 NS NS NS NS 0.899 (0.611–1.322) 0.588 NS NS
HER-2           
    Negative Ref   NS NS NS NS NS NS NS NS
    Positive 2.179 (1.232–3.855) 0.007 NS NS NS NS NS NS NS NS
    Strongly positive 0.651 (0.292–1.451) 0.294 NS NS NS NS NS NS NS NS
Hormonal therapy NS NS 0.537 (0.335–0.859) 0.009 NS NS 0.733 (0.575–0.933) 0.012 0.682 (0.503–0.926) 0.014
Anemia 4.939 (2.875–8.484) <0.001 5.160 (3.428–7.767) <0.001 3.192 (2.489–4.094) <0.001 4.104 (3.310–5.089) <0.001 2.849 (2.205–3.680) <0.001
  1. Abbreviations: LRFS local relapse-free survival, LNMFS lymph node metastasis-free survival, DMFS distant metastasis-free survival, RFS relapse-free survival, OS overall survival, ER estrogen receptor, PR progesterone receptor, HER-2 Human Epidermal Growth Factor Receptor-2, HR hazard ration, CI confidence interval, Ref: Reference group; NS: No significance.
\